Belletti D, Grabrucker A M, Pederzoli F, Menrath I, Cappello V, Vandelli M A, Forni F, Tosi G, Ruozi B
Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
WG Molecular Analysis of Synaptopathies, Neurology Dept., Neurocenter of Ulm University, Ulm, Germany; Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany.
Int J Pharm. 2016 Sep 10;511(1):331-340. doi: 10.1016/j.ijpharm.2016.07.022. Epub 2016 Jul 12.
The biocompatibility of polymers, lipids and surfactants used to formulate is crucial for the safe and sustainable development of nanocarriers (nanoparticles, liposomes, micelles, and other nanocarriers). In this study, Cholesterol (Chol), a typical biocompatible component of liposomal systems, was formulated in Chol-based solid nanoparticles (NPs) stabilized by the action of surfactant and without the help of any other formulative component. Parameters as type (Solutol HS 15, cholic acid sodium salt, poly vinyl alcohol and Pluronic-F68), concentration (0.2; 0.5 and 1% w/v) of surfactant and working temperature (r.t. and 45°C) were optimized and all samples characterized in terms of size, zeta potential, composition, thermal behavior and structure. Results demonstrated that only Pluronic-F68 (0.5% w/v) favors the organization of Chol chains in structured NPs with mean diameter less than 400nm. Moreover, we demonstrated the pivotal role of working temperature on surfactant aggregation state/architecture/stability of Chol-based nanoparticles. At room temperature, Pluronic-F68 exists in solution as individual coils. In this condition, nanoprecipitation of Chol formed the less stable NPs with a 14±3% (w/w) of Pluronic-F68 prevalently on surface (NP-Chol/0.5). On the contrary, working near the critical micelle temperature (CMT) of surfactant (45°C), Chol precipitates with Pluronic-F68 (9±5% w/w) in a compact stable matricial structure (NP-Chol/0.5-45). In vitro studies highlight the low toxicity and the affinity of NP-Chol/0.5-45 for neuronal cells suggesting their potential applicability in pathologies with a demonstrated alteration of neuronal plasticity and synaptic communication (i.e. Huntington's disease).
用于制剂的聚合物、脂质和表面活性剂的生物相容性对于纳米载体(纳米颗粒、脂质体、胶束及其他纳米载体)的安全和可持续发展至关重要。在本研究中,胆固醇(Chol)作为脂质体系统的一种典型生物相容性成分,被制备成基于胆固醇的固体纳米颗粒(NPs),该纳米颗粒通过表面活性剂的作用得以稳定,且无需任何其他制剂成分的辅助。对表面活性剂的类型(Solutol HS 15、胆酸钠盐、聚乙烯醇和普朗尼克 - F68)、浓度(0.2;0.5和1% w/v)以及工作温度(室温及45°C)等参数进行了优化,并对所有样品的尺寸、zeta电位、组成、热行为和结构进行了表征。结果表明,只有普朗尼克 - F68(0.5% w/v)有利于胆固醇链在平均直径小于400nm的结构化纳米颗粒中有序排列。此外,我们证明了工作温度对基于胆固醇的纳米颗粒的表面活性剂聚集状态/结构/稳定性起着关键作用。在室温下,普朗尼克 - F68以单个线圈的形式存在于溶液中。在这种情况下,胆固醇的纳米沉淀形成了稳定性较差的纳米颗粒,表面普遍含有14±3%(w/w)的普朗尼克 - F68(NP - Chol/0.5)。相反,在接近表面活性剂的临界胶束温度(CMT,45°C)下工作时,胆固醇与普朗尼克 - F68(9±5% w/w)以紧密稳定的基质结构沉淀(NP - Chol/0.5 - 45)。体外研究突出了NP - Chol/0.5 - 45对神经元细胞的低毒性和亲和力,表明它们在具有神经元可塑性和突触通讯明显改变的疾病(即亨廷顿舞蹈症)中的潜在适用性。